Subcutaneous Amivantamab Displays Activity in Recurrent/Metastatic HNSCC
In a critical step towards progress in the battle against cancer, Amivantamab, administered subcutaneously, has demonstrated significant activity in the management of Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
In light of serious safety incidents: The Food and Drug Administration has enforced a partial clinical hold on the Lorigerlimab trial aimed at treating gynecological cancers. This development underlies the stringent regulatory steps for ensuring patient safety during clinical trials.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Efforts to refine the management of toxicities caused by Immune-Checkpoint Inhibitor in Melanoma skin cancer have noted considerable improvements. These advancements reveal the continued commitment of the medical community to optimize cancer treatment procedures.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
In a major development: The FDA has granted Fast Track Designation to a therapy called SRN-101. This is specifically intended for the treatment of Recurrent High-Grade Glioma, thus offering promising future avenues for patients dealing with this condition.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
A novel small molecule demonstrating early activity against previously-treated Multiple Myeloma has been discovered. This breakthrough suggests promising potential for enhancing the effectiveness of existing treatments.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A comparative study between Protons and Photons used in OPSCC (Oropharyngeal Squamous Cell Carcinoma) treatment has been conducted with regard to Quality of Life outcomes. This research further contributes valuable data in implementing highly patient-centric treatment plans.
